12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Deals

Seattle Genetics, Abbott deal

Seattle Genetics and Abbott expanded a 2011 deal for Seattle Genetics' antibody-drug conjugate (ADC) technology. Abbott will pay Seattle Genetics $25 million for rights to...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >